French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update - 01/11/23
Endorsed by the Investigation Network On Venous Thrombo-Embolism (INNOVTE) and the French Speaking Society of Respiratory Diseases (SPLF)

for the
Best Practice Guidelines for VTE Management Working Group
Abstract |
Background |
In recent years, knowledge about cancer associated thrombosis has evolved considerably.
Methods |
Practical guidelines were drafted on the initiative of the INNOVTE FCRIN Network, led by the French Speaking Society of Respiratory Diseases (SPLF), by a coordinating group, a writing group, and a review group, with the involvement of different scientific societies practicing in various settings. The method followed the "Clinical Practice Guidelines" process of the French National Authority for Health (HAS).
Results |
After a literature review, guidelines were formulated, improved, and then validated by the working groups. These guidelines addressed multiple aspects of the disease and management from the data of available clinical trials and observational studies : epidemiology, initial treatment, treatment duration, extended treatment, recurrent thrombosis, central venous catheter thrombosis, incidental thrombosis, treatment in case of thrombocytopenia.
Conclusion |
These evidence-based guidelines are intended to guide the practical management of patients with cancer associated thrombosis
Le texte complet de cet article est disponible en PDF.Keywords : cancer, thrombosis, treatment, guidelines
Plan
Vol 84
Article 101056- novembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?